Comparing the current results to its competitors, Oric Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 86.3 %, recorded in the same quarter.
August 27, 2025
CSIMarket.com Insight: ORIC Pharmaceuticals’ Strategic Position and Market Dynamics In an era where innovation in oncology is paramount, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage company that primarily focuses on developing treatments targeting therapeutic resistance mechanisms, is beginning to navigate turbulent waters. Recent announcements and financial results have raised critical questions regarding the company s competitive positioning and its ability to capture market attention.On August 27, 2025, ORIC Pharmaceuticals disclosed its upcoming participation in several investor conferences slated for September. This strategic engagement aims to enhance visibility and foster relationsh...
April 8, 2024
brings you the latest findings from ORIC Pharmaceuticals, as presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The company showcased promising preclinical data on two of their programs, highlighting their potential to revolutionize cancer treatment.ORIC-944, a potent and selective allosteric PRC2 inhibitor, stole the spotlight with its superior preclinical drug properties and extended clinical half-life. The research findings suggest that ORIC-944 possesses a best-in-class profile when compared to competitor PRC2 inhibitors. Allosteric inhibition of PRC2 has shown immense potential in combating cancer by preventing the enzymatic activity of the PRC2 complex responsible f...
January 8, 2024
Metastatic prostate cancer, a devastating disease that affects thousands of men worldwide, requires innovative approaches to improve patient outcomes. ORIC Pharmaceuticals, a pioneering biopharmaceutical company, has recently provided compelling initial Phase 1b data for their promising therapeutic candidate, ORIC-944, in metastatic prostate cancer. This article focuses on the potential best-in-class profile demonstrated by ORIC-944, underlining its remarkable half-life, robust target engagement, well-tolerated safety profile, and supporting evidence to advance its development in combination therapy.ORIC-944: A Breakthrough in Metastatic Prostate Cancer Treatment:ORIC Pharmaceuticals research endeavors have...
Marker Therapeutics Inc is a biotechnology company that aims to develop and commercialize novel T cell immunotherapies for the treatment of cancer. Their business model focuses on leveraging their expertise in cellular engineering to develop proprietary technologies and therapies that can be licensed or partnered with other organizations for further development and commercialization.
Pds Biotechnology Corp is a biotechnology company that focuses on developing innovative immunotherapies for the treatment of various cancers and infectious diseases. Their business model revolves around leveraging their proprietary Versamune® platform to design and develop novel vaccines and immunotherapies with enhanced efficacy compared to traditional approaches. Pds Biotechnology Corp also collaborates with pharmaceutical companies and research institutions to advance their product pipeline and explore potential applications of their technology.
Rigel Pharmaceuticals Inc is a biotechnology company that operates on a research and development business model. They focus on discovering, developing, and commercializing innovative small molecule drugs to address unmet medical needs. Their goal is to use their scientific expertise and strategic partnerships to bring new treatments to patients in various therapeutic areas.
Sources:
Oric Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Oric Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
